Aptar Pharma's preservative-free multi-dose ophthalmic squeeze dispense launched in the US
First preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.
Aptar Pharma has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma’s innovative preservative-free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.
Following the worldwide trend towards safe, patient-friendly, cost-effective and preservative-free multi-dose dispensers such as Aptar Pharma's OSD system, the new over-the-counter (OTC) eye care product is able to maintain its status as the gold standard in lubricant eye drops.
The first OTC product marketed with OSD in the US
The newly released OTC eye drop product relieves dry, red, itchy eyes by providing preservative free eye drops in a revolutionary multi-dose bottle. Aptar Pharma has worked closely with a leading eye care company to improve patient safety, achieve dosing accuracy and maintain product integrity. The proprietary, sterile, lubricant eye drop formulation, contains 10 mL of solution, equivalent to more than 250 drops and claims to remain sterile for up to 3 months after first use. It is being supported by extensive television advertising and is available nationwide in pharmacies, supermarkets, and other retailers.
Meeting the needs of patients and consumers
Dry eye patients and consumers use lubricant eye drops on a regular basis, and often for the rest of their lives. It is well proven that preserved medications may cause unpleasant and sometimes serious side effects. Consequently, removing preservatives from the formulation by using Aptar Pharma’s OSD system is appreciated by the increasing number of patients and consumers experiencing eye irritation or allergic responses with preserved formulations.
Key benefits of Aptar Pharma’s OSD technology platform
Aptar Pharma’s OSD system is the result of more than 10 years of development for the delivery of preservative free ophthalmic solutions. European patients and consumers have benefited from this technology for years with more than 70 commercial references available on the market.
For the newly released over-the-counter product, Aptar Pharma’s OSD system delivers the following features:
· Unrivalled microbiological safety
· Intrinsic intuitiveness of a squeezable container
· User friendliness for all age groups due to a low actuation force
· Precise and reproducible drop ejection
· Ergonomic and pocket size design.
“The launch of Aptar Pharma’s OSD system in the US is a welcome event for patients suffering from eye irritations as it offers them significant benefits compared with standard therapy. This is also a very important milestone for Aptar Pharma in its international development strategy,” said Matthias Birkhoff, Vice President Business Development for Aptar Pharma’s Consumer Health Care Division.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance